在渐进的超核性麻中补充卡尼丁.
Devika Dixit1, Yang Zhao2, Olgert Bardhi3
1Department of Internal Medicine, University of Florida, Gainesville, Florida, USA.
概括
本案例报告强调,补充卡尼丁可以改善渐进性上核性麻 (PSP) 的症状. 一名患有PSP和卡尼丁缺乏症的患者在接受了勒沃卡尼丁治疗后显示出显著的症状改善.
科学领域:
- 神经科学是一个神经科学.
- 线粒体生物学 线粒体生物学
- 营养科学 营养科学
背景情况:
- 线粒体功能障碍与神经退行性疾病,如渐进性超核性麻 (PSP) 有关.
- 卡尼丁对于线粒体的能量生产至关重要.
- PSP是一种严重的帕金森综合征,治疗选择有限.
研究的目的:
- 报告在患有渐进性上核性麻的患者中补充卡尼丁的第一个病例.
- 调查卡尼丁补充在管理PSP症状中的潜在益处.
主要方法:
- 一名65岁的男性患者患有PSP和营养不良,被诊断患有肉素缺乏症.
- 患者接受了勒沃卡尼丁补充剂.
- 监测临床症状和物理治疗进展.
主要成果:
- 勒沃卡尼丁补充剂导致患者的震,疲劳和身体功能明显改善.
- 在住院后继续服用补充剂时,观察到持续的症状改善.
结论:
- 卡尼丁补充可能是渐进性上核性麻的有益辅助疗法.
- 需要进一步的研究,以了解卡尼丁在PSP病理生理学中的作用,并探索其他营养干预措施.
更多相关视频
08:16Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
Published on: March 4, 2014
31.7K
06:07Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
Published on: June 23, 2023
1.5K
相关概念视频
Parkinson's Disease: Treatment
216
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
216
Parkinson's Disease: Overview
476
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
476
Skeletal Muscle Relaxants: Adverse Effects
335
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
335
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
614
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
614
